View Future GrowthTegoScience 과거 순이익 실적과거 기준 점검 0/6TegoScience 의 수입은 연평균 -35.6%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 15.2%의 비율로 증가했습니다. 매출은 연평균 6.8%의 비율로 감소해 왔습니다.핵심 정보-35.64%순이익 성장률-35.65%주당순이익(EPS) 성장률Biotechs 산업 성장률11.70%매출 성장률-6.79%자기자본이익률-17.29%순이익률-143.46%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트분석 기사 • Mar 28We Think That There Are Some Issues For TegoScience (KOSDAQ:191420) Beyond Its Promising EarningsTegoScience Inc.'s ( KOSDAQ:191420 ) robust recent earnings didn't do much to move the stock. We believe that...모든 업데이트 보기Recent updates공시 • Mar 17TegoScience Inc., Annual General Meeting, Mar 27, 2026TegoScience Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea분석 기사 • Jan 28Is TegoScience (KOSDAQ:191420) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Nov 27New major risk - Revenue and earnings growthEarnings have declined by 9.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.2b revenue, or US$4.2m). Market cap is less than US$100m (₩128.1b market cap, or US$87.6m).분석 기사 • Sep 01Is TegoScience (KOSDAQ:191420) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Jul 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.2b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₩6.8b revenue, or US$5.0m). Market cap is less than US$100m (₩135.2b market cap, or US$98.9m).공시 • May 29TegoScience Inc. announced that it has received KRW 27 billion in fundingOn May 27, 2025, TegoScience Inc. closed the transaction.New Risk • May 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Revenue is less than US$5m (₩6.8b revenue, or US$4.9m).Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩17,950, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 5.3% over the past three years.분석 기사 • Mar 28We Think That There Are Some Issues For TegoScience (KOSDAQ:191420) Beyond Its Promising EarningsTegoScience Inc.'s ( KOSDAQ:191420 ) robust recent earnings didn't do much to move the stock. We believe that...공시 • Mar 07TegoScience Inc., Annual General Meeting, Mar 28, 2025TegoScience Inc., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South KoreaNew Risk • Jan 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₩6.9b revenue, or US$4.7m). Market cap is less than US$100m (₩135.7b market cap, or US$93.0m).Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩14,720, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 30% over the past three years.New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩120.9b market cap, or US$84.1m).Valuation Update With 7 Day Price Move • Dec 02Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩12,360, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past three years.New Risk • Nov 06New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩7.0b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (₩7.0b revenue, or US$5.0m). Market cap is less than US$100m (₩137.6b market cap, or US$98.1m).Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩17,300, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 29% over the past three years.Valuation Update With 7 Day Price Move • Aug 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩16,000, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 43% over the past three years.New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩122.1b (US$89.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩122.1b market cap, or US$89.5m).New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.6b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩137.6b market cap, or US$99.7m).New Risk • Mar 22New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.06% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).New Risk • Nov 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩81.3b market cap, or US$61.3m).Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₩13,450, the stock trades at a trailing P/E ratio of 79.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 40% over the past three years.Is New 90 Day High Low • Feb 23New 90-day low: ₩26,100The company is down 2.0% from its price of ₩26,700 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.분석 기사 • Feb 16Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?TegoScience (KOSDAQ:191420) has had a rough month with its share price down 6.9%. It seems that the market might have...분석 기사 • Jan 12How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?A look at the shareholders of TegoScience Inc. ( KOSDAQ:191420 ) can tell us which group is most powerful. Institutions...Is New 90 Day High Low • Dec 22New 90-day high: ₩30,650The company is up 6.0% from its price of ₩28,850 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 14% over the same period.분석 기사 • Dec 08Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...Is New 90 Day High Low • Oct 15New 90-day low: ₩26,050The company is down 20% from its price of ₩32,600 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.매출 및 비용 세부 내역TegoScience가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A191420 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 265,827-8,3593,0336,00931 Dec 255,941-7,0123,1325,06530 Sep 256,154-3,2493,9653,80130 Jun 256,516-1,8894,1913,09431 Mar 256,7983,3494,4122,82131 Dec 246,7593,3504,4662,66330 Sep 246,9273,6523,7322,41030 Jun 246,9743,3523,6132,47431 Mar 247,194-2,6593,4752,59331 Dec 237,772-2,3233,6562,57630 Sep 238,016-1,4042,1133,47530 Jun 238,134-1,3012,8702,97131 Mar 238,2022353,7292,02731 Dec 227,6782653,5341,60830 Sep 228,4261,3494,85441230 Jun 228,3411,2544,0141,04431 Mar 228,1624323,5622,06231 Dec 218,3001393,9062,32830 Sep 217,573-4794,1422,42130 Jun 218,235714,0892,28431 Mar 218,4559933,5881,99231 Dec 208,7891,8313,0021,85230 Sep 208,3231,7612,6711,75930 Jun 207,5801,3382,5431,80331 Mar 206,9831,2732,4371,73231 Dec 196,3468562,4091,70030 Sep 196,723-2,0582,6121,72030 Jun 196,849-2,1422,7631,65931 Mar 197,366-7762,9391,76231 Dec 187,850-1,8263,1641,74330 Sep 188,042-3,0713,2261,76230 Jun 188,245-2,8883,3501,54531 Mar 188,331-7,5153,4131,58331 Dec 178,642-6,0213,3481,56830 Sep 178,568-2,9853,1821,37630 Jun 178,568-2,6103,0001,43331 Mar 178,5497762,8791,41531 Dec 168,3437722,8571,43330 Sep 168,0491,8422,9071,58330 Jun 167,9811,8412,8451,67831 Dec 157,4921,4732,9251,605양질의 수익: A191420 은(는) 현재 수익성이 없습니다.이익 마진 증가: A191420는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A191420은 수익성이 없으며 지난 5년 동안 손실이 연평균 35.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 A191420의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: A191420은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(22.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A191420는 현재 수익성이 없으므로 자본 수익률이 음수(-17.29%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/08 08:26종가2026/06/08 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스TegoScience Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Seung-Ho LeeNH Investment & Securities Co., Ltd.
분석 기사 • Mar 28We Think That There Are Some Issues For TegoScience (KOSDAQ:191420) Beyond Its Promising EarningsTegoScience Inc.'s ( KOSDAQ:191420 ) robust recent earnings didn't do much to move the stock. We believe that...
공시 • Mar 17TegoScience Inc., Annual General Meeting, Mar 27, 2026TegoScience Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea
분석 기사 • Jan 28Is TegoScience (KOSDAQ:191420) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Nov 27New major risk - Revenue and earnings growthEarnings have declined by 9.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.2b revenue, or US$4.2m). Market cap is less than US$100m (₩128.1b market cap, or US$87.6m).
분석 기사 • Sep 01Is TegoScience (KOSDAQ:191420) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Jul 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.2b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Revenue is less than US$5m (₩6.8b revenue, or US$5.0m). Market cap is less than US$100m (₩135.2b market cap, or US$98.9m).
공시 • May 29TegoScience Inc. announced that it has received KRW 27 billion in fundingOn May 27, 2025, TegoScience Inc. closed the transaction.
New Risk • May 20New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Revenue is less than US$5m (₩6.8b revenue, or US$4.9m).
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩17,950, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 5.3% over the past three years.
분석 기사 • Mar 28We Think That There Are Some Issues For TegoScience (KOSDAQ:191420) Beyond Its Promising EarningsTegoScience Inc.'s ( KOSDAQ:191420 ) robust recent earnings didn't do much to move the stock. We believe that...
공시 • Mar 07TegoScience Inc., Annual General Meeting, Mar 28, 2025TegoScience Inc., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 26, gomdallae-ro 57ga-gil, gangseo-gu, seoul South Korea
New Risk • Jan 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₩6.9b revenue, or US$4.7m). Market cap is less than US$100m (₩135.7b market cap, or US$93.0m).
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩14,720, the stock trades at a trailing P/E ratio of 32.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 30% over the past three years.
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩120.9b market cap, or US$84.1m).
Valuation Update With 7 Day Price Move • Dec 02Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩12,360, the stock trades at a trailing P/E ratio of 27.1x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 39% over the past three years.
New Risk • Nov 06New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩7.0b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (₩7.0b revenue, or US$5.0m). Market cap is less than US$100m (₩137.6b market cap, or US$98.1m).
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩17,300, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 27x in the Biotechs industry in South Korea. Total loss to shareholders of 29% over the past three years.
Valuation Update With 7 Day Price Move • Aug 29Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩16,000, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 43% over the past three years.
New Risk • Aug 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩122.1b (US$89.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₩122.1b market cap, or US$89.5m).
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.6b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩137.6b market cap, or US$99.7m).
New Risk • Mar 22New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.06% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
New Risk • Nov 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩81.3b market cap, or US$61.3m).
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₩13,450, the stock trades at a trailing P/E ratio of 79.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 40% over the past three years.
Is New 90 Day High Low • Feb 23New 90-day low: ₩26,100The company is down 2.0% from its price of ₩26,700 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
분석 기사 • Feb 16Are TegoScience Inc.'s (KOSDAQ:191420) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?TegoScience (KOSDAQ:191420) has had a rough month with its share price down 6.9%. It seems that the market might have...
분석 기사 • Jan 12How Much Of TegoScience Inc. (KOSDAQ:191420) Do Insiders Own?A look at the shareholders of TegoScience Inc. ( KOSDAQ:191420 ) can tell us which group is most powerful. Institutions...
Is New 90 Day High Low • Dec 22New 90-day high: ₩30,650The company is up 6.0% from its price of ₩28,850 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 14% over the same period.
분석 기사 • Dec 08Did You Miss TegoScience's (KOSDAQ:191420) Impressive 137% Share Price Gain?When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Is New 90 Day High Low • Oct 15New 90-day low: ₩26,050The company is down 20% from its price of ₩32,600 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.